Literature DB >> 2807552

Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

A Donohue-Rolfe1, D W Acheson, A V Kane, G T Keusch.   

Abstract

Shiga toxin from Shigella dysenteriae 60R was purified to homogeneity by a novel one-step receptor analog affinity chromatography method. The method was based on the binding affinity of Shiga toxin for a specific disaccharide, Gal alpha 1----4Gal, which was also present in glycoproteins with P1 blood group seroreactivity produced in hydatid cysts from sheep infected with Echinococcus granulosus. Having shown that cyst fluid P1 glycoprotein bound Shiga toxin on a solid phase, a P1 glycoprotein affinity column was made by coupling P1-active substance to Sepharose 4B. Shiga toxin was purified by this method in large quantities (5 to 10 mg/20-liter batch) with a consistently good yield (greater than 80% of starting toxin). Shiga-like toxins I and II (SLT-I and -II, respectively) from Escherichia coli were also purified by the same method. A preparation containing SLT-II and SLT-I purified by receptor analog affinity chromatography was used to raise four monoclonal antibodies (MAbs) that were reactive with SLT-II by enzyme-linked immunosorbent assay. Three of these antibodies also reacted with Shiga toxin, which was the first clear demonstration of cross-reactivity between these toxins. One MAb, 4D1, which was specific for the B subunit of SLT-II and Shiga toxin, neutralized both toxins in a HeLa cell cytotoxicity assay. Two MAbs recognized the A subunit of both SLT-II and Shiga toxin by Western blot (immunoblot) analysis but were unable to neutralize either toxin. In addition, one B-subunit-specific MAb neutralized SLT-II alone, and a previously described Shiga toxin B-subunit-specific MAb was shown to be specific for Shiga toxin but not SLT-II.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807552      PMCID: PMC259922          DOI: 10.1128/iai.57.12.3888-3893.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  BLOOD GROUP P1 SUBSTANCE. I. CHEMICAL PROPERTIES.

Authors:  W T MORGAN; W M WATKINS
Journal:  Bibl Haematol       Date:  1964

2.  The nature of the human blood group P1 determinant.

Authors:  H T Cory; A D Yates; A S Donald; W M Watkins; W T Morgan
Journal:  Biochem Biophys Res Commun       Date:  1974-12-23       Impact factor: 3.575

3.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.

Authors:  N A Strockbine; L R Marques; J W Newland; H W Smith; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

Review 4.  The P blood group system: recent progress in immunochemistry and genetics.

Authors:  D M Marcus; S K Kundu; A Suzuki
Journal:  Semin Hematol       Date:  1981-01       Impact factor: 3.851

5.  Purification and biological characterization of shiga toxin from Shigella dysenteriae 1.

Authors:  J E Brown; D E Griffin; S W Rothman; B P Doctor
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

6.  Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea.

Authors:  A D O'Brien; J W Newland; S F Miller; R K Holmes; H W Smith; S B Formal
Journal:  Science       Date:  1984-11-09       Impact factor: 47.728

7.  Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin.

Authors:  A D O'Brien; M E Chen; R K Holmes; J Kaper; M M Levine
Journal:  Lancet       Date:  1984-01-14       Impact factor: 79.321

8.  Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography.

Authors:  A D O'Brien; G D LaVeck; D E Griffin; M R Thompson
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

9.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

10.  Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

Authors:  A Donohue-Rolfe; G T Keusch; C Edson; D Thorley-Lawson; M Jacewicz
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  46 in total

1.  Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

Authors:  B P Hurley; M Jacewicz; C M Thorpe; L L Lincicome; A J King; G T Keusch; D W Acheson
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin.

Authors:  P L Wagner; D W Acheson; M K Waldor
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

3.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

4.  A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.

Authors:  S B Calderwood; D W Acheson; M B Goldberg; S A Boyko; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

Review 6.  Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum.

Authors:  Maria Teresa Tarragó-Trani; Brian Storrie
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

7.  PCR-based DNA amplification and presumptive detection of Escherichia coli O157:H7 with an internal fluorogenic probe and the 5' nuclease (TaqMan) assay.

Authors:  R D Oberst; M P Hays; L K Bohra; R K Phebus; C T Yamashiro; C Paszko-Kolva; S J Flood; J M Sargeant; J R Gillespie
Journal:  Appl Environ Microbiol       Date:  1998-09       Impact factor: 4.792

8.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.

Authors:  Jenny M Ritchie; Patrick L Wagner; David W K Acheson; Matthew K Waldor
Journal:  Appl Environ Microbiol       Date:  2003-02       Impact factor: 4.792

10.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.